Lora (Lorazepam)

Quick links to important sections

Medically reviewed

Marina Burgos

Last updated on 10/01/2026

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Lora (Lorazepam)

Property Description
Active ingredient Lorazepam
Form Tablet, Oral Solution, Injectable Solution
Pharmacological class Benzodiazepine, CNS Depressant
General purpose Alleviation of tension and induction of sedation
Origin Synthetic Compound

What is Lorazepam and What is its Primary Class?

Lorazepam is a synthetic psychoactive agent that functions as the active ingredient in the medicine Lora, classifying it fundamentally as a benzodiazepine drug. This compound, chemically defined by the formula C15H10Cl2N2O2, places it within the broader pharmacological category of Central Nervous System (CNS) depressants. Lora is recognized as a single active ingredient product, deriving its effect solely from Lorazepam. Its primary classification as a benzodiazepine dictates its ability to modulate specific neural pathways; Lorazepam is used to slow down the nervous system's activity. The medicine acts to calm the brain and body.

How is Lora (Lorazepam) Prepared and What is its General Purpose?

The medicinal entity Lorazepam is prepared in several distinct dosage forms for systemic administration, including the common tablet and oral concentrate solution, as well as a specialized injectable solution. These preparations facilitate different primary routes of administration, allowing the medicine to be taken orally or administered via intramuscular (IM) or intravenous (IV) routes. A key differentiator for Lorazepam is its short-acting profile compared to some other benzodiazepines, which is clinically recognized for managing acute tension states. The overarching purpose of Lorazepam is to diminish excessive neural communication, which is the mechanism underlying its utility as an anxiolytic and a sedative-hypnotic. Lorazepam is recognized as an essential medicine for the treatment of seizures and anxiety. This demonstrates the drug's essential role in managing states of high tension and hyperexcitability to promote stabilization and relaxation, particularly when rapid onset is beneficial for the patient group.

Regulatory References

  1. Lorazepam on WHO's EML

What side effects are possible with Lora (Lorazepam)?

Possible Side Effects and Safety Information

The official safety profile of Lorazepam is structured by its classification as a central nervous system depressant. Adverse reactions are grouped by frequency and affected body systems, as documented in regulatory sources.


Common Adverse Reactions

The most frequent effects, classified as Common (occurring in 1% to 10% of users in clinical trials), are primarily related to CNS depression. These include sedation (sleepiness or drowsiness), dizziness, weakness, and unsteadiness or trouble with balance.

Serious Adverse Reactions and Safety Constraints

The regulatory label carries a serious warning regarding the risk of profound sedation, respiratory depression, coma, and death when Lorazepam is used concurrently with opioids. Other serious, though less frequent, effects documented in the Blood and Lymphatic System Disorders class include rare occurrences of blood cell abnormalities such as agranulocytosis and thrombocytopenia.

Dependence and Withdrawal

A core safety consideration is the risk of developing physical and psychological dependence, which is associated with longer-term use. Abrupt discontinuation following continued use can lead to life-threatening withdrawal reactions, including seizures. The potential for a protracted withdrawal syndrome is also documented.


Population-Specific Safety Notes

Official labeling addresses specific population constraints. Older or debilitated patients are noted as being more susceptible to the sedative effects, increasing the risk of muscle weakness and subsequent falls. The medicine is contraindicated in cases of known hypersensitivity to benzodiazepines and in patients with acute narrow-angle glaucoma. Furthermore, it should not be used in individuals with severe hepatic insufficiency due to the risk of worsening liver function.

Overdose and Emergency Response

The official regulatory profile for Lorazepam overdose is defined by an exaggerated central nervous system depression that necessitates immediate medical intervention. When an overdose is suspected, immediate medical attention must be sought right away, often requiring a visit to the nearest hospital emergency room.

Documented manifestations of overdose include a spectrum of CNS effects, ranging from profound sedation, somnolence, confusion, and slurred speech to severe loss of muscle control, such as unsteadiness and impaired reflexes. Severe outcomes that may be life-threatening include the progression to coma, respiratory arrest, and significant hypotension. The risk of serious adverse outcomes and death is significantly increased when Lorazepam is combined with other central nervous system depressants, such as alcohol or opioids, as explicitly warned in official labeling.

Management is structured around supportive measures, primarily focusing on securing and maintaining the patient's airway and continuous monitoring of vital signs. While the benzodiazepine antagonist Flumazenil is available for treatment, regulatory caution notes that its use may precipitate acute withdrawal reactions and seizures. Pharmacokinetic data indicates that clearance is reduced in elderly subjects, which may result in a prolonged duration of the overdose effects and require extended observation.

Therapeutic Uses of Lora (Lorazepam)

What Lora (Lorazepam) Treats: Main Uses and Benefits

Lorazepam is commonly used to provide short-term relief from conditions marked by excessive psychic and physical tension, worry, and symptoms that create noticeable physiological strain. It is relevant for the management of anxiety disorders and for the temporary relief of symptoms associated with acute episodes. The medication is also considered relevant for short-term symptom stabilization of acute seizures (status epilepticus) and the management of severe agitation, including symptoms related to acute alcohol withdrawal syndrome.

The core benefit is to ease the symptom burden in acute episodes of anxiety and to assist with maintaining a sense of stability when symptoms become temporarily overwhelming. It generally helps to manage symptom clusters that may become intense or disruptive. Furthermore, Lorazepam is used for managing symptoms associated with the need for calming or sedation, which assists with reducing apprehension when temporary assistance is required before medical or surgical procedures.

Quick Fact: Relief for Acute Distress
Primary Focus: Generally applied in clinical settings that involve acute or unstable symptom patterns.

Eligibility and Restrictions for Use

Who Can and Cannot Use Lora (Lorazepam) — Official Regulatory Information

Eligibility for Lorazepam is strictly defined by regulatory bodies based on age, physiological status, and pre-existing medical conditions.


Eligibility Factor Official Regulatory Statement
Populations Contraindicated Hypersensitivity to any benzodiazepine or formulation component; Acute narrow-angle glaucoma; Severe hepatic insufficiency and/or hepatic encephalopathy (caution, sometimes absolute contraindication); Severe respiratory insufficiency; Myasthenia Gravis (in some jurisdictions).
Age-Related Rules Children younger than 12 years: Safety and efficacy for oral use are not established. Elderly or Debilitated Patients: Use requires special caution due to increased susceptibility to effects and risk of falls.
Restricted Use/Caution Patients with compromised respiratory function (e.g., COPD, sleep apnea); Patients with a history of alcohol or drug abuse; Patients with impaired renal or hepatic function.
Pregnancy and Lactation Pregnancy: Former FDA Category D. Use late in pregnancy carries a risk of neonatal withdrawal syndrome. Breastfeeding: The drug is excreted into milk; use requires caution and monitoring of the infant for sedation or poor feeding.

Official labeling does not recommend use in patients with a primary depressive disorder or psychosis, as benzodiazepines may worsen these conditions. Use is typically allowed for adults and children aged 12 years and older (oral) when no contraindications are present.

What should I know about interactions with other medicines?

Interactions with other medicines and products

The use of Lorazepam with certain other medicines and substances can lead to clinically significant interactions, which are classified based on the potential severity and mechanism.

Pharmacodynamic Interactions

Concomitant use with other Central Nervous System (CNS) depressants significantly increases the risk of enhanced sedation, respiratory depression, coma, and death. Medicines in this category include:

  • Opioids
  • Antipsychotics and other psychotropic agents
  • Sedative Antihistamines
  • Alcohol: Consumption of alcohol must be avoided due to the significant potentiation of depressant effects.

Pharmacokinetic (Metabolic) Interactions

Lorazepam is primarily metabolized via glucuronidation. Medicines that inhibit this pathway can increase Lorazepam's concentration and prolong its effects.

Interacting Substance Interaction Mechanism Resulting Constraint
Valproate Inhibits glucuronidation Increased Lorazepam plasma levels (requires dose reduction)
Probenecid Inhibits glucuronidation Increased Lorazepam half-life (requires dose reduction)

Population-Specific Constraints

Special caution and monitoring are necessary when Lorazepam is given with interacting drugs to elderly patients, who are generally more susceptible to profound CNS depressant effects. Use of Lorazepam is generally restricted in cases of severe hepatic insufficiency due to the increased risk of precipitating hepatic encephalopathy.

Mechanism of Action

Lorazepam's action is primarily targeted within the Central Nervous System (CNS). It functions as a positive allosteric modulator at the GABA-A receptor complex, a ligand-gated chloride ion channel.

Lorazepam selectively binds to the benzodiazepine site, typically located at the interface of the alpha and gamma subunits of the receptor. This binding event induces a conformational change in the receptor protein, which does not directly open the channel but instead enhances the receptor's affinity for its endogenous neurotransmitter, gamma-aminobutyric acid (GABA).

When GABA binds concurrently, the potentiated interaction results in a significant increase in the frequency of chloride ion channel opening. The resultant influx of negatively charged chloride ions (Cl^-) into the postsynaptic neuron causes the membrane potential to become more negative, a process known as hyperpolarization. This stabilization of the cellular plasma membrane elevates the threshold required for neuronal excitation and impulse transmission. The overall downstream cascade is a widespread reduction in neuronal excitability throughout the CNS, leading to systemic central nervous system depression.

Dosage and Administration Information

The administration of Lorazepam is characterized by its route and formulation, with specific dose ranges and duration limits. It is available for oral use as tablets, an oral concentrate, and an extended-release capsule, and for parenteral use as an injectable solution administered intramuscularly (IM) or intravenously (IV).

Standard Dosage and Frequency

For anxiety, the usual oral starting dosage is 2 mg to 3 mg per day, typically given in divided doses two or three times daily. The total daily dosage can range from 2 mg to 6 mg, though a maximum of 10 mg per day has been described. For insomnia related to stress, a single dose of 2 mg to 4 mg is usually administered at bedtime. Parenteral use, such as the IV administration of 4 mg for acute episodes like status epilepticus, is reserved for monitored settings.

Administration Requirements

The oral concentrate is intended to be diluted immediately before use in a liquid or semi-solid food. Extended-release capsules are designed to be swallowed whole but can be opened and the contents mixed with applesauce if necessary, to be consumed immediately without chewing. The use of Lorazepam is intended for short-term management, generally not exceeding two to four months, and discontinuation involves a gradual dose reduction.

Population Adjustments

For older adults and debilitated patients, the initial oral dosage is recommended to be reduced to 1 mg to 2 mg per day in divided doses, with the initial daily dose generally not exceeding 2 mg.

Recent Clinical Evidence

Evidence for Short-Term Relief of Anxiety Symptoms

Lorazepam was studied for the temporary management of conditions characterized by fluctuating or episodic manifestations of anxiety, primarily using short-term, randomized controlled trials (RCTs), systematic reviews, and meta-analyses. Research examined outcomes related to symptom severity reduction and changes in overall clinical status. Findings describe patterns observed in these short-term studies, and trials comparing lorazepam to a placebo reported measurements of patterns related to anxiety scale scores. Studies including older adults also monitored outcomes reflecting daily functioning, such as memory and physical coordination. What remains uncertain is the evidence for long-term use; systematic clinical trials have not established evidence for sustained use beyond approximately four months, and limited information exists for long-term outcomes.


Evidence for the Management of Acute Seizures

The research was evaluated in settings focusing on conditions associated with acute or disruptive episodes like status epilepticus (prolonged seizures). The main research consists of comparative RCTs against other treatments, involving both adults and pediatric patients. Research examined outcomes describing episodic or acute changes, such as the cessation of convulsive activity within minutes and the sustained seizure-free interval. A notable limitation is that this research applies only to the ultra-short-term effects of an acute intervention, and long-term effects are not fully established.


Evidence for Acute Agitation and Pre-Procedure Sedation

The evidence base includes systematic reviews and RCTs applied in research contexts involving fluctuating or unstable symptoms of tension and agitation, often utilizing combination therapy. Study outcomes examined measurements of agitation severity using standardized scales and the time required to achieve a target sedation level. Due to the frequent use of combination regimens, the specific measurements of outcomes related to physiological strain provided by lorazepam alone may be challenging to isolate, meaning subgroup findings are uncertain.


Research Gaps

The overall evidence base highlights several areas where certainty remains low. A primary gap is the limited information for long-term outcomes, as the majority of systematic evidence focuses on short-term relief. Research was evaluated in specific populations, including pediatric patients and older adults, but generally, data for certain groups remain insufficient for broad conclusions.

Frequently Asked Questions (FAQ)

Common questions about Lora (Lorazepam) (FAQ)


Q: How quickly is Lora (Lorazepam) supposed to start working?

The speed at which Lora (Lorazepam) begins to work depends on the form used. For the oral form, official clinical information indicates that the highest concentration in the bloodstream typically occurs about two hours after the medicine is taken. The effects of the intravenous (IV) form are much faster, beginning within one to five minutes of administration.


Q: How long does the effect of Lora (Lorazepam) typically last in the body?

The noticeable effects of a single oral dose are generally described in official sources as lasting for approximately 6 to 8 hours. The time it takes for the amount of active medicine in the plasma to be reduced by half, known as the elimination half-life, is about 12 hours.


Q: Can Lora (Lorazepam) be used for a short period only?

Yes, official product information states that the medicine is indicated for the short-term relief of anxiety symptoms. Continuous use should generally be limited, and the duration of treatment is usually recommended to be as short as possible to manage symptoms.


Q: What is the difference between Lora (Lorazepam) and a standard anxiety pill?

Lora (Lorazepam) is officially classified as a benzodiazepine drug, which acts as a depressant on the central nervous system. This classification places it in a different pharmacological category than many other treatments used for anxiety, such as SSRIs, which modify serotonin levels. Regulatory documents do not use the term 'standard anxiety pill' as a formal classification.


Q: Is Lora (Lorazepam) available in different forms, like liquid or injection?

Yes, regulatory documents indicate that Lorazepam is prepared in several forms. These include standard oral tablets, an oral concentrate solution, extended-release capsules, and a sterile injectable solution.


Q: What happens if I miss a scheduled dose of Lora (Lorazepam)?

The common pattern found in official instructions describes taking the missed dose as soon as it is remembered, unless it is nearly time for the next dose. In that case, official information describes skipping the missed dose entirely and continuing with the regular schedule. This approach is described to help prevent accidentally taking too much medicine.


Q: Can Lora (Lorazepam) cause a feeling of being 'tired' the next day?

Official safety information lists sedation (sleepiness or drowsiness) as a very common side effect related to the medicine's depressant effect on the central nervous system. Because the medicine has a relatively long half-life, these sedative effects may occasionally persist and result in a feeling of being tired the next day.


Q: Does Lora (Lorazepam) interact with common pain relievers?

Regulatory documents contain a specific warning regarding the use of Lorazepam with other central nervous system depressants, which includes strong opioid pain relievers. These combinations increase the risk of severe effects. Specific warnings for common over-the-counter pain medicines like ibuprofen or acetaminophen are typically not listed in the official product information.


Q: Does Lora (Lorazepam) affect memory?

Yes, the official safety profile for Lorazepam includes a risk of memory loss (amnesia). The risk is noted in regulatory documents, often in the context of acute use for sedation.


Q: Can Lora (Lorazepam) be taken on an empty stomach?

The administration requirements for Lorazepam tablets do not explicitly state a prohibition against taking them on an empty stomach. The official guidance specifically addresses the need for the oral concentrate to be diluted and for the extended-release capsules to be swallowed whole or mixed with applesauce.


Q: Does Lora (Lorazepam) lose effectiveness over time with continuous use?

Official product information notes that for some indications, such as treating seizures, tolerance to the effects may gradually occur. For anxiety, regulatory information emphasizes that continued use carries a risk of dependence, and the evidence base for long-term effectiveness is limited.


Q: Are there known cases of Lora (Lorazepam) tolerance developing?

Yes, official documentation describes the potential for tolerance to the effects of Lorazepam, particularly in the context of long-term use for specific conditions like resistant seizures. Tolerance is described as the gradual need for higher amounts of medicine to achieve effects comparable to those seen initially.


Q: Is Lora (Lorazepam) considered a strong or weak medication?

Regulatory documents classify Lorazepam as a high-potency benzodiazepine. This technical classification means that the medicine produces its intended effects at relatively low doses. The terms 'strong' or 'weak' are not used in official regulatory labeling.


Q: Is Lora (Lorazepam) known by any other names?

Yes, the active ingredient is called Lorazepam, which is the generic name. It is also sold under several brand names in different markets, such as Ativan, Lorazepam Intensol, and Loreev XR.


Q: Do you have to take Lora (Lorazepam) every day?

The requirement to take Lora (Lorazepam) daily depends entirely on the condition being addressed. The medicine is sometimes prescribed to be taken in divided doses daily for anxiety management. It is also used as a single dose specifically at bedtime for stress-related insomnia.


Q: Is it true that Lora (Lorazepam) is sometimes used before surgery?

Yes, the injectable form of Lorazepam has an official indication for use as a preanesthetic medication in adult patients. Its purpose in this setting is to induce sedation, relieve anxiety, and decrease the patient's ability to remember events related to the day of surgery.


Q: What are some of the most common reasons people stop taking Lora (Lorazepam)?

While the regulatory documents do not list specific reasons for discontinuation, the side effects reported most frequently in clinical trials are the most frequent effects reported in clinical trials that may be associated with discontinuation. These common central nervous system effects include excessive sedation, dizziness, and unsteadiness.


Q: Is it safe to drive after taking Lora (Lorazepam)?

Official labeling contains a strong warning that Lorazepam can cause sleepiness or dizziness and can impair a person's ability to think and their motor skills. Regulatory documents caution against driving, operating heavy machinery, or engaging in other hazardous activities, as the medicine may impair performance and judgment.


Q: Does Lora (Lorazepam) interact with caffeine?

Official drug interaction checkers typically do not list a major, severe interaction between Lorazepam and caffeine. However, it is a stimulant that has the potential to counteract the medicine's intended sedative and calming effects.


Q: What does the term 'half-life' mean for Lora (Lorazepam)?

In regulatory pharmacology, the half-life refers to the amount of time required for the concentration of the medicine in the body's bloodstream to decrease by exactly 50%. The mean half-life for the active form of lorazepam is approximately 12 hours.


Q: Does Lora (Lorazepam) interact with herbal supplements like St. John's Wort?

Yes, official warnings advise caution, as combining Lorazepam with certain herbal supplements, such as St. John's Wort, may increase the risk of common side effects. These enhanced effects can include greater levels of drowsiness, dizziness, and difficulty concentrating.


Q: Is it okay to stop Lora (Lorazepam) suddenly?

Official labeling contains warnings against this. Abrupt discontinuation or a rapid reduction in dose after continuous use may lead to acute withdrawal reactions, which include life-threatening complications such as seizures. A gradual dose taper is described as necessary.


Q: What should be done if someone accidentally takes too much Lora (Lorazepam)?

Official guidance emphasizes that in situations of accidental ingestion or overdose, the patient requires close medical observation and supportive care to manage symptoms. Official guidance describes immediate contact with emergency services or a poison control center as necessary.


Q: Does Lora (Lorazepam) carry a risk for allergic reactions?

Yes. Lorazepam is formally contraindicated in patients who have a known history of hypersensitivity or allergy to any benzodiazepine or to any component used in the formulation. Official documentation notes that rare but serious allergic reactions have been observed.


Q: Are there different strengths (dosages) of Lora (Lorazepam) tablets?

Yes, regulatory information indicates that Lorazepam tablets are supplied in various dosage strengths. Common strengths available include 0.5 mg, 1 mg, and 2 mg tablets.


Q: Can Lora (Lorazepam) make existing depression worse?

Official precautions advise that in patients with existing depression, the potential for suicide must be considered. Official precautions note that the use of benzodiazepines alone in these patients is generally not recommended in the regulatory documents, and that depression may potentially emerge or worsen during their use.


Q: What kind of monitoring is typically involved when taking Lora (Lorazepam)?

Official labeling emphasizes that certain populations, particularly older or debilitated patients, should be monitored frequently and their dosage adjusted carefully. The general product information does not typically mandate routine specific laboratory tests for all users.


Q: What happens in the body when Lora (Lorazepam) starts to wear off?

As the medicine’s concentration in the body’s plasma declines, the enhancement of the brain’s inhibitory signals begins to decrease. This leads to a gradual reversal of the central nervous system depression, meaning the effects of sedation and calmness begin to subside.


Q: Is Lora (Lorazepam) available over-the-counter anywhere?

No. In the United States, official regulatory labeling classifies Lorazepam as a prescription drug (Rx Only) and a Federal Controlled Substance (Schedule IV). This classification means it is legally restricted and cannot be purchased over-the-counter.


Q: Is Lora (Lorazepam) metabolized by the liver?

Yes, regulatory pharmacokinetic information confirms that Lorazepam is extensively processed in the liver through a process called glucuronidation. This process converts the active drug into an inactive substance (a metabolite) so that the body can excrete it.

How should Lora (Lorazepam) be stored and disposed of?

How to Store and Dispose of Lorazepam

Official labeling dictates distinct storage conditions for lorazepam based on its formulation to maintain stability. Lorazepam tablets must be stored at 20 C to 25 C (68 F to 77 F) and kept in a tightly closed, light-resistant container. In contrast, the oral concentrate and solution for injection require refrigeration at 2 C to 8 C (36 F to 46 F) and protection from light.

Formulation Required Temperature Shelf-Life Constraint
Tablets Controlled Room Temp. None stated
Oral Concentrate Refrigerate (2 C to 8 C) Discard 90 days after opening

As a controlled substance, lorazepam must be kept in a safe place, out of the reach of children. Unused or expired medication should be disposed of securely, preferably through a drug take-back program, or by following specific household disposal guidelines to prevent misuse.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Available in countries:

Equivalent of Lora (Lorazepam) found in:

A-Z Index: